A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.

NCT Number	NCT07704892
Lead Sponsor	GlaxoSmithKline
Conditions	Metabolic Dysfunction-associated Steatohepatitis
Enrollment	380 participants
Start Date	2026-07-20
Primary Completion	2030-10-14 (estimated)
Study Completion	2033-12-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-15